Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31172125 | 1.00 | CASP3 (0.33) | CASP3SENP8SENP7SENP6ALDH1A1 | |
| SCHEMBL23218005 | 0.92 | CASP3 (0.32) | CASP3SENP8SENP7SENP6ALDH1A1 | |
| SCHEMBL29773056 | 0.92 | CASP3 (0.32) | CASP3SENP8SENP7SENP6ALDH1A1 | |
| SCHEMBL25020373 | 0.90 | CASP3 (0.32) | CASP3SENP8SENP7SENP6ALDH1A1 | |
| SCHEMBL23698705 | 0.88 | ALDH1A1 (0.35) | CASP3SENP8SENP7SENP6ALDH1A1 | |
| SCHEMBL28931092 | 0.88 | GBA1 (0.35) | CASP3SENP8SENP7SENP6ALDH1A1 | |
| SCHEMBL7736866 | 0.87 | CASP3 (0.32) | CASP3SENP8SENP7SENP6ALDH1A1 | |
| SCHEMBL29867943 | 0.87 | CASP3 (0.32) | CASP3SENP8SENP7SENP6ALDH1A1 | |
| SCHEMBL17485426 | 0.87 | NPC1 (0.35) | CASP3SENP8SENP7SENP6ALDH1A1 | |
| SCHEMBL23698605 | 0.81 | HTT (0.35) | CASP3SENP8SENP7SENP6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528782-B2 | Prodrugs in the modulation of interleukin | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250127801-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2025080850-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-12152048-B2 | Nitroxoline prodrug and use thereof | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2024-11-26 | — | — | US | disclosed |
| EP-3999499-B1 | PRODRUGS IN THE MODULATION OF INTERLEUKIN | BRISTOL MYERS SQUIBB CO (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20230167082-A1 | PRODRUGS IN THE MODULATION OF INTERLEUKIN | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-01 | — | — | US | disclosed |
| US-20230167082-A1 | PRODRUGS IN THE MODULATION OF INTERLEUKIN | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-01 | — | — | US | disclosed |
| US-11447449-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220213099-A1 | PRODRUG COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2022-07-07 | — | — | US | disclosed |
| EP-3999499-A1 | PRODRUGS IN THE MODULATION OF INTERLEUKIN | Bristol-Myers Squibb Company (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3966212-A1 | PRODRUG COMPOUNDS | Bristol-Myers Squibb Company (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20210363165-A1 | NITROXOLINE PRODRUG AND USE THEREOF | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2021-11-25 | — | — | US | disclosed |
| EP-3858814-A1 | NITROXOLINE PRODRUG AND USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858814-A1 | NITROXOLINE PRODRUG AND USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
| US-20210070698-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-03-11 | — | — | US | disclosed |
| US-20210070698-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-03-11 | — | — | US | disclosed |
| WO-2021011513-A1 | PRODRUGS IN THE MODULATION OF INTERLEUKIN | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2020227337-A1 | PRODRUG COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12152048-B2 | Nitroxoline prodrug and use thereof | NOS1, NOS2, NNT | CASP3 621/4885SENP8 1087/4885SENP7 431/4885 |
| US-20210070698-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | CASP3 2125/4885SENP8 3434/4885SENP7 2814/4885 |
| US-20220213099-A1 | PRODRUG COMPOUNDS | TLR7, TLR4, TLR9 | CASP3 126/4885SENP8 1221/4885SENP7 419/4885 |
| US-12528782-B2 | Prodrugs in the modulation of interleukin | IL2, IL23R, TYK2 | CASP3 573/4885SENP8 3097/4885SENP7 3414/4885 |
| US-20250127801-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DPYD | CASP3 348/4885SENP8 433/4885SENP7 639/4885 |
| US-11447449-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | CASP3 2125/4885SENP8 3434/4885SENP7 2814/4885 |
| US-20210363165-A1 | NITROXOLINE PRODRUG AND USE THEREOF | NOS1, NOS2, NNT | CASP3 621/4885SENP8 1087/4885SENP7 431/4885 |
| US-20230167082-A1 | PRODRUGS IN THE MODULATION OF INTERLEUKIN | TYK2, IL2, IRAK2 | CASP3 277/4885SENP8 2018/4885SENP7 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.